Vendredi 01 Juillet 2022 de 14h00 à 15h00

Julien Marie

CRCL, INSERM U1052/CNRS UMR 5286, Centre Léon Bérard, Université Lyon 1

"Cooperation between Cancer cells and Tregs  to create a potent Immunosuppressive  micro-environment in tumors."


Vendredi 18 Février 2022 de 11h00 à 12h00
Séminaire IRCM

Marie-Caroline Dieu-Nosjean

Immune Microenvironment and Immunotherapy Lab, UMR1135 Inserm, Hopital Pitié-Salpêtriere, Paris.

"Tertiary lymphoid structures: an anti-tumor school for adaptive immune cells and an antibody factory to fight cancer "


Jeudi 18 Novembre 2021 de 11h00 à 12h30
Séminaire IRCM

Olivier de Wever 

University of Gent, Experimental Cancer Research Lab, Belgium

“From spheroids to extracellular vesicles: finding unknown unknowns to create minimum information guidelines and advance biological understanding”


Some more on the speaker:

Since his PhD, he has been working on cancer-associated fibroblasts (CAFs) in colon cancer progression (De Wever et al., FASEBJ 2004, J Pathol 2003, J Cell Science 2004 over 1000 cumulative WOS citations). I He expanded his research into adipose tissue during his post-doc (Lapeire et al., Cancer Res 2014) and the secretory mechanisms of pro-metastatic signals (Hendrix et al., JNCI 2010, Cancer Res 2010). His current lab woks on tumor-environment interactions  including design of model systems (De Jaeghere et al., Biomaterials 2018), response to therapy of CAFs (Tommelein et al., Cancer Res 2018), and exploitation of CAFs as therapy (De Vlieghere et al., Biomaterials 2015) and extracellular vesicles with the Hendrix lab (De Wever and Hendrix EMBOJ 2019). 

Jeudi 04 Novembre 2021 à 14h00
Séminaire IRCM

Hervé Técher

Institut de Génétique Humaine, CNRS/Université de Montpellier

Understanding the link(s) between replication stress and inflammation in cancer biology.


mercredi 15 septembre à 15h, séminaire Mabimprove

Andrew Kruse

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School

“VHH antibody fragments as tools to interrogate transmembrane receptor signaling”

"Research in Dr Kruse's lab aims to elucidate the molecular basis of transmembrane signaling through the use of biochemistry, pharmacological studies, and structural biology. He is particularly interested in signaling pathways with connections to human health and disease, including G protein-coupled receptors and other transmembrane receptors. In the long term, he aims to leverage a detailed molecular understanding of these pathways to facilitate the development of new and better therapeutics."

Plus d'informations :

Jeudi 09 Septembre 2021 de 11h30 à 13h00
séminaire MabImprove-IRCM

Lloyd Bod

Evergrande Center for Immunologic Diseases, Harvard Medical School 

“Tumor-infiltrating B cells: Friends or Foes?”


Vendredi 17 Septembre 2021 de 11h00 à 13h00
Séminaire IRCM

Maria Casanova

CNIO, Madrid

Tissue-resident macrophages: helpers of early-stage lung tumor development”

Contact : Antonio Maraver



Vendredi 10 Décembre 2021 de 11h00 à 12h00
Séminaire IRCM

Pablo José Fernandez

Instituto Madrileño de Estudios Avanzados, Madrid, Espagne

"Molecular perspectives of short-term fasting as a nutritional strategy during cancer development and management”


More details

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés